Bernadette Brennan1, Gian Luca De Salvo2, Daniel Orbach3, Angela De Paoli2, Anna Kelsey4, Peter Mudry5, Nadine Francotte6, Max Van Noesel7, Gianni Bisogno8, Michela Casanova9, Andrea Ferrari9. 1. Paediatric Oncology, Royal Manchester Children's Hospital, Manchester, UK. Electronic address: Bernadette.brennan@cmft.nhs.uk. 2. Clinical Trials and Biostatistics Unit, IRCCS Istituto Oncologico Veneto, Padova, Italy. 3. Pediatric, Adolescent, Young Adult Department, Institut Curie, Paris, France. 4. Department of Diagnostic Paediatric Histopathology, Royal Manchester Children's Hospital, Manchester, UK. 5. Department of Pediatric Oncology, University Children's Hospital, Brno, Czech Republic. 6. Department of Pediatrics, CHC-Clinique Esperance, Montegnée, Belgium. 7. Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands. 8. Pediatric Hematology and Oncology Division, Padova University, Padova, Italy. 9. Fondazione IRCCS Istituto Nazionale Tumori Milano, Milan, Italy.
Abstract
BACKGROUND: Extracranial malignant rhabdoid tumours (MRT) are rare lethal childhood cancers that often occur in infants and have a characteristic genetic mutation in the SMARCB1 gene. The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) conducted a multinational prospective study of registered cases of extracranial MRT to test an intensive multimodal approach of treatment for children with newly diagnosed extracranial MRT. METHODS: Between December 2005 and June 2014, we prospectively registered 100 patients from 12 countries with a diagnosis of MRT tumour at an extracranial site on the EpSSG Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study (NRSTS 2005). They were all treated on a standard multimodal protocol of surgery, radiotherapy, and chemotherapy over 30 weeks as follows: vincristine, cyclophosphamide, and doxorubicin (VDCy) at weeks 1, 10, 13, 22, and 28; vincristine was also given alone on weeks 2, 3, 11, 12, 14, 15, 23, 24, 29, and 30. Cyclophosphamide, carboplatin, and etoposide (Cy*CE) was given at weeks 4, 7, 16, 19, and 25. Radiotherapy was recommended for all primary tumour sites and all sites of metastatic disease. RESULTS: Forty-three patients completed the protocol treatment. Median follow-up for alive patients of the complete cohort was 44.6 months (range 11.5-84.6). For the whole cohort, the 3-year event-free survival (EFS) was 32.3% (95% confidence interval [CI] 23.2-41.6%) with a 3-year overall survival (OS) of 38.4% (95% CI 28.8-47.9%). For localised disease, the 4-year EFS was 39.3% (95% CI 28.2-50.1%) with a 4-year OS of 40.1% (95% CI 28.4-51.5%). For metastatic disease, the 2-year EFS was 8.7% (95% CI 1.5-24.2%) with a 2-year OS of 13.0% (95% CI 3.3-29.7%). Multivariable analysis disclosed that all patients ≤1 year of age were associated with at higher risk of death (hazard ratio [HR]: 2.6; 95% CI 1.0-6.8; p-value = 0.0094). Risk of death was also related with gender in metastatic patients (HR for males: 2.9, 95% CI 1.0-8.0; p-value = 0.0077). CONCLUSIONS: The EpSSG NRSTS 2005 protocol of intensive therapy can be delivered to extracranial MRT patients, with a possible improvement in outcome. The outcome, however, remains poor for patients who progress or with metastatic disease.
BACKGROUND:Extracranial malignant rhabdoid tumours (MRT) are rare lethal childhood cancers that often occur in infants and have a characteristic genetic mutation in the SMARCB1 gene. The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) conducted a multinational prospective study of registered cases of extracranial MRT to test an intensive multimodal approach of treatment for children with newly diagnosed extracranial MRT. METHODS: Between December 2005 and June 2014, we prospectively registered 100 patients from 12 countries with a diagnosis of MRT tumour at an extracranial site on the EpSSG Non-Rhabdomyosarcoma Soft Tissue Sarcoma 2005 Study (NRSTS 2005). They were all treated on a standard multimodal protocol of surgery, radiotherapy, and chemotherapy over 30 weeks as follows: vincristine, cyclophosphamide, and doxorubicin (VDCy) at weeks 1, 10, 13, 22, and 28; vincristine was also given alone on weeks 2, 3, 11, 12, 14, 15, 23, 24, 29, and 30. Cyclophosphamide, carboplatin, and etoposide (Cy*CE) was given at weeks 4, 7, 16, 19, and 25. Radiotherapy was recommended for all primary tumour sites and all sites of metastatic disease. RESULTS: Forty-three patients completed the protocol treatment. Median follow-up for alive patients of the complete cohort was 44.6 months (range 11.5-84.6). For the whole cohort, the 3-year event-free survival (EFS) was 32.3% (95% confidence interval [CI] 23.2-41.6%) with a 3-year overall survival (OS) of 38.4% (95% CI 28.8-47.9%). For localised disease, the 4-year EFS was 39.3% (95% CI 28.2-50.1%) with a 4-year OS of 40.1% (95% CI 28.4-51.5%). For metastatic disease, the 2-year EFS was 8.7% (95% CI 1.5-24.2%) with a 2-year OS of 13.0% (95% CI 3.3-29.7%). Multivariable analysis disclosed that all patients ≤1 year of age were associated with at higher risk of death (hazard ratio [HR]: 2.6; 95% CI 1.0-6.8; p-value = 0.0094). Risk of death was also related with gender in metastatic patients (HR for males: 2.9, 95% CI 1.0-8.0; p-value = 0.0077). CONCLUSIONS: The EpSSG NRSTS 2005 protocol of intensive therapy can be delivered to extracranial MRT patients, with a possible improvement in outcome. The outcome, however, remains poor for patients who progress or with metastatic disease.
Authors: Kevin X Liu; Natalie B Collins; Katie A Greenzang; Elissa Furutani; Kevin Campbell; Andrew Groves; Elizabeth A Mullen; Suzanne Shusterman; Jennifer Spidle; Karen J Marcus; Brent R Weil; Christopher B Weldon; A Lindsay Frazier; Katherine A Janeway; Allison F O'Neill; Jennifer W Mack; Steven G DuBois; David S Shulman Journal: Pediatr Blood Cancer Date: 2020-07-19 Impact factor: 3.167
Authors: Alessandro Carugo; Rosalba Minelli; Luigi Sapio; Melinda Soeung; Federica Carbone; Frederick S Robinson; James Tepper; Ziheng Chen; Sara Lovisa; Maria Svelto; Samirkumar Amin; Sanjana Srinivasan; Edoardo Del Poggetto; Sara Loponte; Francesca Puca; Prasenjit Dey; Gabriel G Malouf; Xiaoping Su; Liren Li; Dolores Lopez-Terrada; Dinesh Rakheja; Alexander J Lazar; George J Netto; Priya Rao; Alessandro Sgambato; Anirban Maitra; Durga N Tripathi; Cheryl L Walker; Jose A Karam; Timothy P Heffernan; Andrea Viale; Charles W M Roberts; Pavlos Msaouel; Nizar M Tannir; Giulio F Draetta; Giannicola Genovese Journal: Cancer Cell Date: 2019-02-11 Impact factor: 38.585
Authors: Karolina Nemes; Pascal D Johann; Stefanie Tüchert; Patrick Melchior; Christian Vokuhl; Reiner Siebert; Rhoikos Furtwängler; Michael C Frühwald Journal: Cancer Manag Res Date: 2022-02-09 Impact factor: 3.989
Authors: Juri Fuchs; Anastasia Murtha-Lemekhova; Markus Kessler; Fabian Ruping; Patrick Günther; Alexander Fichtner; Dominik Sturm; Katrin Hoffmann Journal: Cancers (Basel) Date: 2022-01-06 Impact factor: 6.639
Authors: Julian Kolorz; Salih Demir; Adrian Gottschlich; Iris Beirith; Matthias Ilmer; Daniel Lüthy; Christoph Walz; Mario M Dorostkar; Thomas Magg; Fabian Hauck; Dietrich von Schweinitz; Sebastian Kobold; Roland Kappler; Michael Berger Journal: Curr Oncol Date: 2021-12-26 Impact factor: 3.677